[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-synctial-virus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-synctial-virus":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,75,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100641572","infant-rsv-immunity-study-100641572",false,"NCT07653347","Infant RSV Immunity Study","Understanding the Impact of Early-life RSV Infections on Infant Immunity and Long-term Health","IRIS","Inclusion Criteria:\n\nBirthing parent\u002Fchild pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital.\n\nExclusion Criteria:\n\nSevere pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely \\\u003C 35 weeks of gestation, or with chronic medical conditions).",true,"ALL","6 Months",{"count":21,"type":22},300,"ESTIMATED","OBSERVATIONAL","Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\\\u003C4 months) versus late (\\>6-9 months) in infancy.",[26,27],"Respiratory Synctial Virus","Asthma Childhood",[29,30,31,32],"cohort study","Immune response","infants","season of birth","RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-17","ACTUAL",{"date":39,"type":37},"2026-01-15",{"date":41,"type":22},"2029-12-01",{"name":43,"class":44},"University of British Columbia","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100609673","clinical-validation-of-the-aptitude-medical-systems-metrix-respiratory-panel-test-in-at-homenon-laboratory-settings-100609673","NCT07217639","Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home\u002FNon-Laboratory Settings","Inclusion Criteria:\n\n1. Participant or guardian understands and is able and willing to provide written informed consent, and assent where applicable, prior to study enrollment.\n2. Participant is currently exhibiting signs\u002Fsymptoms of respiratory tract infection including but not limited to fever, cough, sore throat, runny nose, myalgia, headache, chills, new loss of taste or smell, or fatigue. Participant must still be exhibiting symptoms on the day of specimen collection. Days post symptom onset is not to exceed 14 days.\n3. Participant or guardian agrees to read, and is able to read with understanding, the Quick Reference Instructions (QRI) prior to beginning the execution of each of the tests.\n4. Participant or guardian is able and willing to contribute the required swab specimens for testing and understands and is able and willing to sign the study informed consent.\n5. Participant is willing to provide all samples and run tests for the specified investigational devices.\n\nExclusion Criteria:\n\n1. Participant does not understand and\u002For is not able and willing to sign the study informed consent and\u002For assent.\n2. Participant or guardian is not able to comply with nasal swab collection requirements following the Quick Reference Instructions (QRI).\n3. Participant is not currently exhibiting respiratory tract infection symptoms.\n4. Participant has previously participated in the study.\n5. Participant is not able to tolerate specimen collection.\n6. Participant is currently undergoing or has within the past thirty (30) days undergone treatment with prescription medication to treat SARS-CoV-2 infection, including but not limited to Remdesivir (Veklury®), Nirmatrelvir\u002FRitonavir (Paxlovid®), Molnupiravir (LagevrioTM) or receiving convalescent plasma therapy for SARS-CoV- 2.\n7. Participant is currently undergoing or has within the past thirty (30) days undergone an inhaled influenza vaccine (FluMist®), or antiviral treatment, including but not limited to Amantadine (Symmetrel®), Rimantadine (Flumadine®), Zanamivir (Relenza®), Oseltamivir (Tamiflu®), Baloxavir Marboxil (Xofluza®), Amantadine (Symmetrel®), Rimantadine (Flumadine®), or Peramivir (Rapivab®).\n8. Participant is currently undergoing or has within the past thirty (30) days undergone antiviral treatment for RSV, including but not limited to Ribavirin (Virazole®), RSV-IGIV (RespiGam®), Palivizumab (Synagis®), or Nirsevimab-alip (Beyfortus®).\n9. Participants who have had a nasal wash or aspirate as part of their standard of care treatment on day of study visit prior to the study sample collection.\n10. Participants who have had recent craniofacial injury or surgery, including to correct deviation of the nasal septum, within the previous six (6) months.\n11. Participants who do not understand\u002Fread the English language.",{"count":53,"type":22},2000,"INTERVENTIONAL",[56],"NA","The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix Respiratory Panel Test for the detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory syncytial virus, and Rhinovirus in anterior nares (AN) swab samples. Additional sites may be added to the study in order to meet minimum subject\u002Fsample enrollment requirements and geographic prevalence of respiratory virus infections. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay for the detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory Syncytial Virus, and Rhinovirus.",[59,60,61,26,62,63],"COVID -19","Influenza A","Influenza B","RSV","Rhinovirus","NOT_YET_RECRUITING","2025-10-14",{"date":67,"type":37},"2025-10-16",{"date":69,"type":22},"2025-11-01",{"date":71,"type":22},"2026-09-01",{"name":73,"class":74},"Aptitude Medical Systems","INDUSTRY",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":18,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":45},"100572618","respiratory-syncytial-virus-infection-in-exacerbations-of-chronic-obstructive-pulmonary-diasease-the-recode-study-100572618","NCT06735612","Respiratory Syncytial Virus Infection in Exacerbations of Chronic Obstructive Pulmonary Diasease: the RECODE Study","RECODE","Inclusion Criteria:\n\n* Female or male\n* ≥50 years of age\n* Seeking urgent medical attention because of ECOPD, as defined by the Rome consensus definition: \"in a patient with COPD, an exacerbation is an event characterized by dyspnea and\u002For cough and sputum that worsen over \\\u003C14 d, which may be accompanied by tachypnoea and\u002For tachycardia and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways\"\n\nExclusion Criteria:\n\n* Previous RSV vaccination (other vaccines will be allowed and recorded)\n* Active cancer (or any other disease) that may alter the immune status of the patient\n* Neurologic disorders that incapacitate the participation of the patient\n* No signing of the informed consent","50 Years",{"count":84,"type":22},892,"The goal of this observational study is to determine the prevalence of respiratory syncytial virus (RSV) infection and evaluate its association with clinical outcomes in patients with chronic obstructive pulmonary disease (COPD) who experience exacerbations during the RSV season (October-April). The main question it aims to answer is:\n\n* What is the prevalence of RSV infection in patients with COPD during exacerbations in the RSV season?\n* Does RSV infection lead to worse clinical outcomes, including hospitalization, longer length of stay, acute cardiovascular events, and\u002For death in patients with COPD exacerbations?\n\nResearchers will compare patients with RSV infection to those without RSV infection to see if RSV infection results in worse clinical outcomes, such as increased hospitalization, longer stays, cardiovascular events, or death.\n\nParticipants will:\n\n* Be adults diagnosed with COPD who present to the emergency department or day hospital due to acute exacerbations of their respiratory symptoms.\n* Receive treatment as per standard clinical care for COPD exacerbations, including long-acting bronchodilators and inhaled corticosteroids, and may complete a course of antibiotics and\u002For oral corticosteroids if prescribed during hospitalization.\n* Undergo diagnostic testing for RSV infection as part of the clinical routine to determine the presence or absence of the virus during their exacerbation.\n* Have clinical outcomes monitored, including hospitalization rate, length of stay, and any acute cardiovascular events, as well as mortality during the exacerbation period.\n* Provide relevant demographic and clinical data, including medical history, COPD severity, comorbidities, and previous exacerbation events.",[26,87,88,89],"COPD","Chronic Obstructive Pulmonary Disease (COPD)","Exacerbation of COPD","2025-02-25",{"date":92,"type":37},"2025-02-26",{"date":94,"type":37},"2024-12-16",{"date":96,"type":22},"2025-09",{"name":98,"class":44},"Fundacio Privada Mon Clinic Barcelona",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":17,"sex":18,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100576395","community---the-covid-19-immunity-study-100576395","NCT06784739","COMMUNITY - the COVID-19 Immunity Study","COMMUNITY","Inclusion Criteria:\n\n* Health care workers: Employment at Danderyd hospital at time of enrollment\n* COVID-19 patients: Admitted to Danderyd Hospital with confirmed SARS-CoV-2 infection at time of enrollment\n\nExclusion Criteria:\n\n* No exclusion criteria","18 Years",{"count":108,"type":22},5500,"The principal aim of the COMMUNITY study is to investigate immune responses following SARS-CoV-2 infection and\u002For vaccination in healthcare workers and hospitalized COVID-19 patients. The study aims to enroll a total of 5,000 healthcare workers and 500 COVID-19 patients. All participants are enrolled at Danderyd Hospital in Stockholm, Sweden. Participants will be followed every four months with blood and mucosal sampling in addition to demographic and clinical data provided by the participants and from national registries.\n\nPrimary outcome:\n\n\\- Antibody responses in blood and mucosa following SARS-CoV-2 infection and\u002For vaccination\n\nSecondary outcomes:\n\n* Cellular immune responses following SARS-CoV-2 infection and\u002For vaccination\n* Antibody responses in blood and mucosa following following Influenza A\u002FB infection and\u002For vaccination\n* Antibody responses in blood and mucosa following following RSV A\u002FB infection\n\nBlood and mucosal samples are collected every 4 months and at tighter intervals in sub studies. PCR testing is conducted upon symptoms of respiratory infections and with regular intervals regardless of symptomatology in sub studies. Participants provide detailed demographic and clinical data through a smart phone application-based questionnaire. Data on infection and vaccination history is collected from national registries",[111,26,112,113],"COVID 19","Influenza Virus","SARS-CoV-2 Virus",[115,116,117,118,119],"COVID-19","Mucosal immunity","Pandemic","Vaccination","Secretory IgA","2025-01-16",{"date":122,"type":37},"2025-01-20",{"date":124,"type":37},"2020-04-15",{"date":126,"type":22},"2027-04",{"name":128,"class":44},"Danderyd Hospital",2]